Zevra Therapeutics, Inc. Earnings Per Share (Diluted)
Zevra Therapeutics, Inc. (ZVRA) reported Earnings Per Share (Diluted) of $0.14 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-05
- Zevra Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was $0.14, a 88.43% decline year-over-year.
- Zevra Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was $0.60.
- Zevra Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was $0.20.
- Zevra Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.01.
- Zevra Therapeutics, Inc. earnings per share, diluted for fiscal 2025 was $1.35.
- Zevra Therapeutics, Inc. earnings per share, diluted for fiscal 2024 was -$2.28.
- Zevra Therapeutics, Inc. earnings per share, diluted for fiscal 2021 was -$2.11.
- Zevra Therapeutics, Inc. earnings per share, diluted for fiscal 2020 was -$3.21.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.14 10-Q · filed 2026-08-05 | $0.74 10-Q · filed 2026-08-05 | $0.94 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.95 derived: net income ÷ weighted average shares · filed 2026-08-05 | |||
| 2026-03-31 | $0.60 10-Q · filed 2026-05-06 | $0.81 derived: net income ÷ weighted average shares · filed 2026-05-06 | $0.82 derived: net income ÷ weighted average shares · filed 2026-05-06 | $2.00 derived: net income ÷ weighted average shares · filed 2026-08-05 | |||
| 2025-12-31 | $0.20 derived: net income ÷ weighted average shares · filed 2026-03-09 | $0.20 derived: net income ÷ weighted average shares · filed 2026-03-09 | $1.39 derived: net income ÷ weighted average shares · filed 2026-08-05 | $1.35 10-K · filed 2026-03-09 | |||
| 2025-09-30 | -$0.01 10-Q · filed 2025-11-05 | $1.20 derived: net income ÷ weighted average shares · filed 2026-08-05 | $1.16 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $1.21 10-Q · filed 2026-08-05 | $1.16 10-Q · filed 2026-08-05 | |||||
| 2025-03-31 | -$0.06 10-Q · filed 2026-05-06 | ||||||
| 2024-12-31 | -$2.28 10-K · filed 2026-03-09 | ||||||
| 2024-09-30 | -$0.69 10-Q · filed 2025-11-05 | -$1.59 10-Q · filed 2025-11-05 | |||||
| 2024-06-30 | -$0.48 10-Q · filed 2025-08-12 | -$0.87 10-Q · filed 2025-08-12 | |||||
| 2021-12-31 | -$0.08 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$0.14 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$0.49 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$2.11 10-K · filed 2022-03-31 | |||
| 2021-09-30 | -$0.06 10-Q · filed 2021-11-10 | -$0.42 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$2.16 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | -$0.40 10-Q · filed 2021-08-13 | -$2.42 10-Q · filed 2021-08-13 | |||||
| 2021-03-31 | -$2.49 10-Q · filed 2021-05-14 | ||||||
| 2020-12-31 | -$1.07 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$1.75 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$1.63 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$3.21 10-K · filed 2022-03-31 | |||
| 2020-09-30 | -$0.68 10-Q · filed 2021-11-10 | -$0.04 10-Q · filed 2020-10-30 | -$0.52 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$2.08 10-Q · filed 2021-11-10 | -$0.13 10-Q · filed 2020-10-30 | ||
| 2020-06-30 | $0.21 10-Q · filed 2021-08-13 | $0.01 10-Q · filed 2020-08-12 | -$1.43 10-Q · filed 2021-08-13 | -$0.09 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | -$1.92 10-Q · filed 2021-05-14 | ||||||
| 2019-09-30 | $0.06 10-Q · filed 2020-10-30 | -$0.65 10-Q · filed 2020-10-30 | |||||
| 2019-06-30 | -$0.33 10-Q · filed 2020-08-12 | -$0.78 10-Q · filed 2020-08-12 | |||||
| 2018-09-30 | -$0.94 10-Q · filed 2019-11-14 | -$3.33 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | -$0.91 10-Q · filed 2019-08-13 | -$2.41 10-Q · filed 2019-08-13 | |||||
| 2017-12-31 | -$0.72 10-K · filed 2018-03-30 | ||||||
| 2017-09-30 | -$0.68 10-K · filed 2018-03-30 | ||||||
| 2017-06-30 | -$0.44 10-Q · filed 2018-08-10 | -$1.56 10-Q · filed 2018-08-10 | |||||
| 2017-03-31 | -$1.11 10-K · filed 2018-03-30 | ||||||
| 2016-12-31 | -$0.68 10-K · filed 2018-03-30 | ||||||
| 2016-09-30 | -$0.92 10-K · filed 2018-03-30 | ||||||
| 2016-06-30 | -$0.58 10-K · filed 2018-03-30 | -$1.36 10-Q · filed 2017-08-10 | |||||
| 2016-03-31 | -$0.20 10-K · filed 2018-03-30 | ||||||
| 2015-12-31 | -$0.64 10-K · filed 2017-03-10 | ||||||
| 2015-09-30 | -$0.68 10-K · filed 2017-03-10 | ||||||
| 2015-06-30 | -$2.45 10-K · filed 2017-03-10 | -$4.91 10-Q · filed 2016-08-11 | |||||
| 2015-03-31 | -$2.50 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |